Abstract 386P
Background
Searching for specific targets in cancer diagnosis and treatment is one of the most important problems in clinical oncology. We put forward a new concept of the emergence of tumor-specific epitopes of integral membrane proteins by changing their topology under mutations, glycosylation and tumor conditions including low pH and hypoxia on the model of Na-dependent phosphate-cotransporter NaPi2b. NaPi2b (SLC34A2, NaPi-IIb, NPT2b) belongs to the SLC34A2 transporters family and is involved in maintaining phosphate homeostasis in the human body. NaPi2b express in a number of normal and malignant tissues, including ovarian, breast and triple-negative breast cancer. It is an integral membrane protein with a large extramembrane domain 4 (EMD4, 234-362 aa), 8 transmembrane domains, N - and C - ends located in the cytoplasm.
Methods
We have cloned the epitope for antibodies MX35 and L2 (20/3) within 311-340 aa region of NaPi2b, which recognition depends on disulfide bonds, glycosylation and is canceled by the mutation at the T330V position. Topology of the protein undergoing significant changes in hypoxia and low pH conditions.
Results
N-terminal domain of NaPi2b can be localized outside the cells during hypoxia and low pH and return to its primary topology at the inner leaflet membrane in normoxia conditions. This reorientation makes it as a potential tumor-specific domain.
Conclusions
The obtained data are of both fundamental and applied importance in the development of new targeted antitumor drugs of high specificity.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Kazan Federal University.
Funding
Russian Government Program of Competitive Growth of KFU.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
51P - Enhancing the anti-breast tumour activity of STING through a novel sting transcriptional regulator
Presenter: Hanchu Xiong
Session: Poster display session
Resources:
Abstract
52P - Reverse Warburg effect-related mitochondrial activity and 18F-FDG uptake in invasive ductal carcinoma
Presenter: Byung Wook Choi
Session: Poster display session
Resources:
Abstract
53P - Phase II study of atorvastatin in combination with radiotherapy and temozolomide in patients with glioblastoma (ART): Final analysis report
Presenter: Abdullah Altwairgi
Session: Poster display session
Resources:
Abstract
54P - Association between Parkinson’s disease and brain tumours: A nationwide population-based cohort study
Presenter: Joo-hyun Park
Session: Poster display session
Resources:
Abstract
55P - Toxicity profiles of treatment with modern fractionated radiotherapy, contemporary stereotactic radiosurgery, or transsphenoidal surgery in non-functioning pituitary macroadenoma
Presenter: Kevin Sheng-Po Yuan
Session: Poster display session
Resources:
Abstract
56P - Hippocampal avoidance in WBRT for metastases: Comparative neurocognitive and dosimetric assessment
Presenter: Vibhay Pareek
Session: Poster display session
Resources:
Abstract
57P - Multidisciplinary brain metastasis clinic: Is it effective and worthwhile?
Presenter: Annu Rajpurohit
Session: Poster display session
Resources:
Abstract
58P - Functional status as a determinant prognostic factor for overall survival in adult patients with medulloblastoma treated with chemotherapy and radiotherapy
Presenter: Juan Ayala Alvarez
Session: Poster display session
Resources:
Abstract
59P - Pattern of care in high-grade gliomas after recurrence
Presenter: Nandini Menon
Session: Poster display session
Resources:
Abstract
60P - Five fractions plus “SRS” boost combined with temozolamide for newly diagnosed and recurrent glioblastoma multiforme (GBM)
Presenter: Azhar Rashid
Session: Poster display session
Resources:
Abstract